Illumina (NASDAQ:ILMN) Director Sells $24,021,184.78 in Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 106,543 shares of Illumina stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $225.46, for a total value of $24,021,184.78. Following the sale, the director owned 1,172,289 shares in the company, valued at $264,304,277.94. The trade was a 8.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $215.59 on Friday. The company has a market capitalization of $32.55 billion, a P/E ratio of 40.22, a price-to-earnings-growth ratio of 3.03 and a beta of 1.45. The company’s 50-day moving average is $194.05 and its 200 day moving average is $155.60. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $231.81.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Elyxium Wealth LLC bought a new position in shares of Illumina in the fourth quarter valued at approximately $25,000. TD Waterhouse Canada Inc. purchased a new position in Illumina during the fourth quarter valued at approximately $26,000. Laurel Wealth Advisors LLC bought a new stake in Illumina during the 4th quarter worth approximately $26,000. Fiduciary Financial Advisors bought a new stake in Illumina during the 2nd quarter worth approximately $26,000. Finally, Activest Wealth Management lifted its stake in Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 215 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
• Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
• Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
• Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
• Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
• Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.

Analyst Upgrades and Downgrades

ILMN has been the topic of several research analyst reports. Royal Bank Of Canada upped their price objective on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Barclays raised their target price on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research report on Friday, July 31st. Canaccord Genuity Group upped their price target on Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research report on Monday, August 3rd. TD Cowen increased their price target on Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. lifted their price objective on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.